EU approves Zealand’s Zeydovio for short bowel syndrome
The European Commission has approved Zealand Pharma’s Zeydovio (glepaglutide), a long-acting GLP-2 analog given twice weekly, for adults with short bowel syndrome.
The authorization is valid in all EU member states as well as Iceland, Liechtenstein and Norway. It is based on the pivotal Phase 3 EASE-1 trial, in which glepaglutide significantly reduced patients’ need for parenteral support compared with placebo, together with interim data from the EASE-2 and EASE-3 extension trials and the mechanistic EASE-4 trial.
Zealand is in partnership discussions on future global commercialization of the drug. In the US, the Phase 3 EASE-5 trial is under way to support registration.
“Zeydovio combines proven efficacy with simple twice-weekly dosing, and it has the potential to meaningfully ease the burden of this disease,” says Adam Steensberg, President and CEO of Zealand Pharma.
Updated: November 18, 2026, 08:42 am
Published: November 16, 2026
